Home › Core › ISCC-IDs › 28C7Yha9uQiGf

View ISCC-ID

Core Data

28C7Yha9uQiGf
ISCC-ID - digital asset identifier
CCt88fVHnjHJn-CTXFy8wWeiUGm-CDWaM6eV9g6Ld-CRtQoSKtFLF6U
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with her2+ overexpression

Ledger Reference

coblo
Source Ledger/Blockchain
12400311
N-th ISCC Decleration on source ledger
339fb29d25894ac197e24bdebb470236cc6a0f16263ee425c7f44f34f024fb2f
Hash of block that includes the ISCC-DECLARATION
b1d26a186e2486f4fad73e52c34a1a32cfd63db477c33f7841bdb0c3ae9b2a11
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "A.Yu. Kulikov", "@type": "Person"}, {"name": "A.V. Petrovskiy", "@type": "Person"}, {"name": "Yu.V. Rybchenko", "@type": "Person"}, {"name": "A.R. Skripnik", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://pharmacoeconom.com/netcat_files/401/620/Pharmacoeconomic_analysis_of_lapatinib_treatment_in_metastatic_breast_cancer_with_HER2__overexpression.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Moscow Pharmaceutical Society", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.30809/phe.1.2016.29", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCt88fVHnjHJn-CTXFy8wWeiUGm-CDWaM6eV9g6Ld-CRtQoSKtFLF6U", "propertyID": "ISCC"}], "datePublished": "2016-03-15"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close